Saltar al contenido
Merck
  • Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.

Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.

Nature communications (2021-06-23)
Benedict Tanudjojo, Samiha S Shaikh, Alexis Fenyi, Luc Bousset, Devika Agarwal, Jade Marsh, Christos Zois, Sabrina Heman-Ackah, Roman Fischer, David Sims, Ronald Melki, George K Tofaris
RESUMEN

α-Synuclein is critical in the pathogenesis of Parkinson's disease and related disorders, yet it remains unclear how its aggregation causes degeneration of human dopaminergic neurons. In this study, we induced α-synuclein aggregation in human iPSC-derived dopaminergic neurons using fibrils generated de novo or amplified in the presence of brain homogenates from Parkinson's disease or multiple system atrophy. Increased α-synuclein monomer levels promote seeded aggregation in a dose and time-dependent manner, which is associated with a further increase in α-synuclein gene expression. Progressive neuronal death is observed with brain-amplified fibrils and reversed by reduction of intraneuronal α-synuclein abundance. We identified 56 proteins differentially interacting with aggregates triggered by brain-amplified fibrils, including evasion of Parkinson's disease-associated deglycase DJ-1. Knockout of DJ-1 in iPSC-derived dopaminergic neurons enhance fibril-induced aggregation and neuronal death. Taken together, our results show that the toxicity of α-synuclein strains depends on aggregate burden, which is determined by monomer levels and conformation which dictates differential interactomes. Our study demonstrates how Parkinson's disease-associated genes influence the phenotypic manifestation of strains in human neurons.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti- tirosina hidroxilasa, clon LNC1, ascites fluid, clone LNC1, Chemicon®
Sigma-Aldrich
Anticuerpo anti-AGE (productos finales de glucosilación avanzada), serum, Chemicon®
Sigma-Aldrich
Anti-phospho-α-Synuclein (Ser129) Antibody, clone 81A, clone 81A, from mouse
Sigma-Aldrich
Anti-a-Synuclein, clone 10D2 Antibody, clone 10D2, from mouse, purified by affinity chromatography